Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?

Trial StartnegativeNegative

AI Analysis

Summary

Novartis and Bristol Myers Squibb have paused their autoimmune CAR-T cell therapy studies. The article raises questions about whether these programs can recover from the setback.

Clinical Trial Data

Outcome Details

Studies paused

Importance:6/10

Sentiment:

-0.70

CAR-Tautoimmuneclinical trial pauseNovartisBristol Myers Squibb

Related Companies

$NVS $BMY

Read the original article

Published by yahoo_finance on September 26, 2026 1:25 AM

Read Original